Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04331080 · ClinicalTrials.gov registry record · Phase 2

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

A Phase 2 study of Breast Reconstruction and Scar, sponsored by Xequel Bio.

Completed
Registry status
Phase 2
Development phase
184
Enrollment target
11
Study locations

NCT04331080 is a Phase 2 study of Breast Reconstruction and Scar that has completed, run by Xequel Bio. The registered enrollment target is 184 participants, below the 384-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (52% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04331080, a Phase 2 study of Breast Reconstruction and Scar, has completed, sponsored by Xequel Bio.

COMPLETED
Registry status
Phase 2
Development phase
184 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to evaluate effectiveness of Granexin® gel in reducing scar formation in surgical incisional wounds.

Conditions Studied

Breast Reconstruction Scar Scarring Mammoplasty

Interventions

  • DRUG Vehicle gel
  • DRUG Granexin® gel 100 μM
  • DRUG Granexin® gel 200 μM

Study Locations (11)

Florida

  • Universal Axon Clinical Research - Doral
  • Miami Plastic Surgery - Miami
  • Ibrahim H. Amjad, MD, PA - West Miami

California

  • Private Clinic- David Kulber - Los Angeles
  • Pasadena Surgeons - Pasadena

Illinois

  • Northwestern University - Feinberg School of Medicine - Division of Plastic & Reconstructive Surgery - Chicago

Iowa

  • Iowa Plastic Surgery - Davenport

New York

  • Luxurgery - New York

North Carolina

  • Wake Forest Baptist Hospital - Plastic and Reconstructive Surgery - Winston-Salem

Texas

  • Integrated Aesthetics - Spring

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2020-07-01
Est. Completion 2022-05-26
Phase Phase 2

Sponsor

Xequel Bio

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04331080

The ClinicalTrials.gov registry entry for NCT04331080 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 384-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (52% lower). The listed sponsor is Xequel Bio, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Reconstruction appearing as the primary indexed condition, and to 3 interventions - of which Vehicle gel is the first listed.

NCT04331080 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT04331080 about?

NCT04331080 is a clinical study titled "A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery". The purpose of this study is to evaluate effectiveness of Granexin® gel in reducing scar formation in surgical incisional wounds.

What is the current status of trial NCT04331080?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2020-07-01. Estimated completion is 2022-05-26.

What conditions does trial NCT04331080 study?

This clinical trial studies the following conditions: Breast Reconstruction, Scar, Scarring, Mammoplasty.

What interventions are being tested in trial NCT04331080?

The interventions under investigation include: Vehicle gel (DRUG), Granexin® gel 100 μM (DRUG), Granexin® gel 200 μM (DRUG).

Who is sponsoring clinical trial NCT04331080?

This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04331080 being conducted?

This trial has 11 study locations across California, Florida, Illinois, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Reconstruction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Reconstruction

All registered trials for this condition

Scar

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.